<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00797316</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2410</org_study_id>
    <nct_id>NCT00797316</nct_id>
  </id_info>
  <brief_title>Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension</brief_title>
  <acronym>AIMS</acronym>
  <official_title>An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the blood pressure lowering effect and safety of
      aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy
      when given to metabolic syndrome patients with stage 2 systolic hypertension (mean sitting
      systolic blood pressure [msSBP] ≥ 160 mm Hg and &lt; 200 mm Hg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date>December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP)</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Blood Pressure Response at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Response is defined as a patient with msSBP &lt; 140 mmHg or a decrease from baseline ≥ 20 mmHg in msSBP during eight weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Blood Pressure Control at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Blood pressure control is defined as a patient who achieves a target Blood Pressure of mean sitting Systolic Blood Pressure / mean sitting Diastolic Blood pressure &lt; 140/90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Pulse Pressure</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">532</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren plus Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150 mg or 300 mg taken once daily in oral form</description>
    <arm_group_label>Aliskiren plus Hydrochlorothiazide</arm_group_label>
    <arm_group_label>Aliskiren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.</description>
    <arm_group_label>Aliskiren plus Hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are eligible and able to participate in the study, and who give written
             informed consent before any assessment is performed.

          -  Male or female outpatients ≥ 18 years old.

          -  Patients with stage 2 systolic hypertension. Patients must have a msSBP ≥160 mmHg and
             &lt;200 mmHg at Study Visit 5 (randomization).

          -  Patients who have stage 2 systolic hypertension that meet at least 2 additional
             components of the metabolic syndrome as defined by the National *Cholesterol Education
             program (NCEP) criteria:

               -  Abdominal obesity (waist circumference &gt; than 102 cm for men and &gt; 88 cm for
                  women)

               -  Current triglycerides ≥ 150 mg/dL or medical treatment for this condition.

               -  Current HDL- Cholesterol &lt;40 mg/dL in men and &lt;50 mg/dL in women or medical
                  treatment for this condition.

               -  Fasting glucose &gt;100 mg/dL and &lt;126 mg/dL

        Exclusion Criteria:

          -  Office blood pressure measured by cuff (msDBP ≥ 110 mmHg and or msSBP ≥ 200 mmHg) at
             any visit.

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer.

          -  Use of aliskiren and/or a fixed dose combination of aliskiren HCTZ or participation in
             a clinical trial that had aliskiren and/or aliskiren HCTZ as treatment within 30 days
             of Visit 1.

          -  History of hypersensitivity to any of the medications or to drugs belonging to a
             similar therapeutic class (diuretics or renin inhibitors) as the study drugs.

          -  History or evidence of secondary form of hypertension.

          -  Refractory hypertension, defined as unresponsive to triple drug therapy at the maximum
             dose of each drug, one of which must be a diuretic, and not at blood pressure goal
             (140/90mmHg). Therapy with a fixed dose combination of two active substances represent
             two drugs.

          -  Patients on 4 or more antihypertensive medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bloodpressureresearch.com</url>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <results_first_submitted>December 14, 2010</results_first_submitted>
  <results_first_submitted_qc>December 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2011</results_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>aliskiren</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>systolic blood pressure</keyword>
  <keyword>diastolic blood pressure</keyword>
  <keyword>stage 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren/HCTZ</title>
          <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren</title>
          <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren/HCTZ</title>
          <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren</title>
          <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="267"/>
            <count group_id="B2" value="265"/>
            <count group_id="B3" value="532"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="11.09"/>
                    <measurement group_id="B2" value="53.5" spread="10.87"/>
                    <measurement group_id="B3" value="53.9" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP)</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP)</title>
          <population>Full analysis set</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.38" spread="1.01"/>
                    <measurement group_id="O2" value="-20.15" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <population>Full analysis set</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.26" spread="0.59"/>
                    <measurement group_id="O2" value="-6.90" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Blood Pressure Response at Week 8</title>
        <description>Response is defined as a patient with msSBP &lt; 140 mmHg or a decrease from baseline ≥ 20 mmHg in msSBP during eight weeks of treatment.</description>
        <time_frame>8 weeks</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Blood Pressure Response at Week 8</title>
          <description>Response is defined as a patient with msSBP &lt; 140 mmHg or a decrease from baseline ≥ 20 mmHg in msSBP during eight weeks of treatment.</description>
          <population>full analysis set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4"/>
                    <measurement group_id="O2" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Blood Pressure Control at Week 8</title>
        <description>Blood pressure control is defined as a patient who achieves a target Blood Pressure of mean sitting Systolic Blood Pressure / mean sitting Diastolic Blood pressure &lt; 140/90 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Blood Pressure Control at Week 8</title>
          <description>Blood pressure control is defined as a patient who achieves a target Blood Pressure of mean sitting Systolic Blood Pressure / mean sitting Diastolic Blood pressure &lt; 140/90 mmHg.</description>
          <population>Full analysis set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7"/>
                    <measurement group_id="O2" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Pulse Pressure</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren</title>
            <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Pulse Pressure</title>
          <population>Full analysis set</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.96" spread="0.74"/>
                    <measurement group_id="O2" value="-13.33" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren/HCTZ</title>
          <description>Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.</description>
        </group>
        <group group_id="E2">
          <title>Aliskiren</title>
          <description>Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

